Back to search

Article

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term Experience

2023-05-16

Abstract excerpt

PURPOSE: This study examined the effects of Regorafenib (Reg) on progression-free survival (PFS), overall survival (OS) and adverse events (AEs) in mCRC patients who underwent targeted treatment and chemotherapy. MATERIALS and METHODS: Patients diagnosed with mCRC who were treated between 2015 and 2023 were retrospectively examined. RESULTS: Reg was administered as a third-line treatment to 84 patients who had und...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
108e172a-a1a7-50bc-a6e3-a0405a976fab
DOI
10.22541/au.168420783.34384591/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceDOI 10.22541/au.168420783.34384591/v1
Evaluation of the efficacy of regorafenib treatment by location and RAS mutation in metastatic colon cancer.Semantic proximity
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.Semantic proximity
[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity
Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.Semantic proximity
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).Semantic proximity
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Semantic proximity
BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer-A Case Series Study Target Therapy of BRAF-Mutated mCRC.Semantic proximity
Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity
Clinical and molecular assessment of regorafenib monotherapy.Semantic proximity
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.Semantic proximity
Select a neighboring publication to make it the new centre.